Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $2.20 by Analysts at UBS Group

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price objective reduced by UBS Group from $5.00 to $2.20 in a report released on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

ZNTL has been the subject of a number of other research reports. Guggenheim cut their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Wedbush reiterated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $9.69.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $2.40 on Tuesday. The firm has a market cap of $171.02 million, a P/E ratio of -0.96 and a beta of 1.86. The company has a 50 day moving average of $3.02 and a 200-day moving average of $3.31. Zentalis Pharmaceuticals has a 12-month low of $2.13 and a 12-month high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. As a group, equities analysts expect that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

Institutional Trading of Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Erste Asset Management GmbH purchased a new position in Zentalis Pharmaceuticals in the 3rd quarter worth approximately $37,000. Paloma Partners Management Co bought a new position in Zentalis Pharmaceuticals in the third quarter valued at $37,000. Aigen Investment Management LP purchased a new stake in Zentalis Pharmaceuticals during the third quarter valued at about $41,000. Capstone Investment Advisors LLC bought a new stake in Zentalis Pharmaceuticals during the third quarter worth about $48,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after purchasing an additional 5,333 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.